Page: 1 of 7

MEDICAL POLICY



MEDICAL POLICY D	ETAILS
Medical Policy Title	Molecular Markers in Fine Needle Aspirates of the Thyroid
Policy Number	2.02.49
Category	Laboratory Test
Original Effective Date	11/19/15
Committee Approval Date	09/15/16, 09/21/17, 12/20/18, 12/19/19, 10/22/20, 10/28/21, 10/20/22
Current Effective Date	10/20/22
Archived Date	N/A
Archived Review Date	N/A
Product Disclaimer	 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit. If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit. If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, the use of a gene expression classifier in fineneedle aspirates of the thyroid (e.g., Afirma Genomic Sequencing Classifier) or mutation analysis in fine-needle aspirates of the thyroid (e.g., ThyroSeq, ThyraMIR Micro RNA/ThyGenX Thyroid Oncogene Panel, Afirma Xpression Atlas (XA)) that are cytologically considered to be indeterminate, atypical or suspicious for malignancy is considered **medically appropriate** when surgical decisions will be based on the test results for thyroid nodules involving the following:
 - A. Cytological diagnosis of atypia of undetermined significance/follicular lesion of either undetermined significance (AUS/FLUS) on fine-needle aspiration (FNA); or
 - B. Cytological diagnosis of follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) on fine-needle aspiration (FNA); or
 - C. Bethesda III or IV on FNA cytology (please refer to the Bethesda criteria in the Policy Rationale Section); AND
 - D. Size greater than 1.0 cm; and
 - E. No clinical suspicion of malignancy based on provider judgment and ultrasonography; and
 - F. No compressive manifestations.

Testing is appropriate once per lifetime per nodule.

II. Based on our criteria and assessment of the peer-reviewed literature, the use of a gene expression classifier in fineneedle aspirates of the thyroid or mutation analysis in fine-needle aspirates of the thyroid not meeting the above criteria are considered **investigational**.

POLICY GUIDELINES

I. Ultrasound features associated with low suspicion of malignancy include:

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49 Page: 2 of 7

Page: 2 of 7

- A. Isoechoic or hyperechoic solid nodules without microcalcifications; or
- B. Mixed solid/cystic nodules without microcalcification; or
- C. Spongiform nodules.
- II. The ThyroSeq v.3 ThyroSeq Genomic Classifier (GC) (CBLPath, Ocala, FL) uses next-generation sequencing technology to interrogate five classes of genetic alterations: (a) point mutations (SNVs); (b) insertions and deletions; (c) gene fusions; (d) gene expression alterations; and (e) copy number alterations (CNAs). The test utilizes a proprietary genomic classifier (GC) that relies on the algorithmic analysis of all detected genetic alterations to report the test result as positive or negative. Per the manufacturer's website, ThyroSeq GC is specifically designed to determine whether a thyroid nodule is benign (not cancerous) or malignant (cancerous) when cytology result is indeterminate. ThyroSeq also provides specific information about genetic makeup of the nodule which allows physicians to determine an individualized course of treatment.
- III. The ThyraMIR Micro RNA/ThyGenX Thyroid Oncogene Panel (Interpace Diagnostics, Parsippany, NJ) is a next generation sequencing panel designed to be used in patients with indeterminate thyroid FNA results. The panel includes sequencing of eight genes associated with papillary thyroid carcinoma (PTC) and follicular carcinomas. The ThyraMIR is a miRNA gene expression classifier and is based on the evaluation of expression of 10 miRNAs. When used in combination, ThyraMIR can identify malignancy in nodules that are negative for ThyGenX which potentially improving overall sensitivity and ability to detect malignancy.
- IV. The Afirma Genomic Sequencing Classifier (Afirma GSC; Veracyte, San Francisco, CA) analyzes the expression of 142 different genes to determine patterns associated with benign finding on surgical biopsy. It is indicated for thyroid nodules that have an indeterminate classification on FNA. Testing is limited to two thyroid nodules.
- V. The Afirma Xpression Atlas (XA) is an RNA sequencing-based test that measures 761 DNA variants and 130 RNA fusions in over 500 genes that have been linked to thyroid cancer. The test may be performed when the Afirma Genomic Sequencing Classifier results are malignant or suspicious to provide additional information that may guide treatment.

DESCRIPTION

Thyroid nodules are common endocrine tumors that appear as palpable nodules in 5% of adults. Up to 50% of women and 20% of men over age 50 are found to have thyroid nodules on ultrasound or autopsy studies. The majority of thyroid nodules are benign but 10-15% may be malignant, most often as papillary thyroid cancer. Fine needle aspiration (FNA) is performed in nodules that require biopsy, with sufficient information obtained to classify the majority of nodules as benign and a smaller percentage as malignant. However, 15-30% of aspirations yield indeterminate cytology including subtypes such as atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS), suspicious for follicular neoplasm (FN) or suspicious for malignancy.

Current guidelines recommend either partial (lobectomy) or complete thyroidectomy for those nodules determined to be malignant and those of indeterminate cytology. On histological evaluation only 15-30% of the thyroid nodules of indeterminate cytology are malignant consequently many patients undergo surgery for benign disease when expectant management or other treatments would have been more appropriate with a retrospective assessment. Due to the limitations of the FNA, other methods to assist in determining whether a nodule is benign or malignant prior to surgery have been developed. The ThyroSeq and ThyGenX thyroid Oncogene panel are two tests for point mutations associated with thyroid cancers using next-generation sequencing. The Afirma Genomic Sequencing Classifier (GSC) analyzes genetic alterations through the use of gene expression profiling.

RATIONALE

Analysis for mutations associated with thyroid cancer in fine needle aspirates (FNA) of the thyroid that are cytologically indeterminate has a high positive predictive value for malignancy. However, patients with an equivocal FNA result would likely proceed to surgery regardless of mutation status, with intraoperative consultation to guide the necessity and extent of surgery. Mutation analysis has the potential to improve the accuracy of an equivocal FNA of the thyroid and may play a role in preoperative risk stratification and surgical planning. Studies suggest that testing for a panel of mutations

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49 Page: 3 of 7

associated with thyroid cancer may allow the appropriate selection of patients for surgical management with an initial total thyroidectomy.

The American Thyroid Association (ATA) statement on Surgical Application of Molecular Profiling for Thyroid Nodules (2015) states that techniques for molecular profiling of thyroid cytology specimens have evolved as adjuncts to guide the appropriate management of cytologically indeterminate nodules. However, it must be stressed that the utility of any molecular test is only applicable clinically when combined with clinical and sonographic risk factors for malignancy and with understanding of the prevalence of malignancy for the Bethesda cytologic categories at the reporting institution. Future studies on further refinements and expansion of gene sets in analytic panels will likely improve the diagnostic accuracy of molecular analyses of thyroid cytology specimens and offer promise for personalizing surgical therapy, with the potential for cost and risk reduction in the diagnostic and therapeutic approaches to treating differentiated thyroid cancer.

The 2022 NCCN Guidelines for Thyroid Carcinoma state that molecular diagnostics may be useful to allow reclassification of follicular lesions, i.e., follicular neoplasm, atypia of undetermined significance (AUS), or follicular lesions of undetermined significance (FLUS) as either more or less likely to be benign or malignant based on the genetic profile. If molecular testing, in conjunction with clinical and ultrasound features, predicts a risk of malignancy comparable to the risk of malignancy seen with a benign FNA cytology (approximately 5% or less), consider nodule surveillance. Molecular markers should be interpreted with caution and in the context of clinical, radiographic, and cytologic features of each individual patient. Molecular diagnostic testing to detect individual mutations (e.g., BRAF V600E, RET/PTC, RAS, PAX8/PPAR) or pattern recognition approaches using molecular classifiers may be useful in the evaluation of FNA samples that are indeterminate to assist in management decisions. The BRAFV600E mutation occurs in about 45% of patients with papillary carcinoma and is the most common mutation. Some studies have linked the BRAFV600E mutation to poor prognosis, especially when occurring with TERT promoter mutation. The choice of the precise molecular test depends on the cytology and the clinical questions being asked. Indeterminate groups include follicular or Hürthle cell neoplasms and AUS/FLUS. The NCCN Panel recommends consideration of molecular diagnostic testing for these indeterminate groups. Molecular diagnostic testing may include multigene assays (e.g., GEC) or individual mutational analysis. In addition to their utility in diagnostics, molecular markers may drive decisions related to targeted therapy for advanced disease and inform eligibility for some clinical trials. The presence of some mutations may have prognostic importance.

In 2007, the National Cancer Institute (NCI) Thyroid FNA State of Science Conference, developed the Bethesda System for Reporting Thyroid Cytopathology. The purpose of the conference was to develop a uniform reporting system for thyroid FNA to facilitate effective communication among cytopathologists, endocrinologists, surgeons, radiologists, and other health care providers. The reporting system was revised in 2017 and reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced.

Risk	Definition	Diagnostics
Category		
Ι	Nondiagnostic or	Cyst fluid only
	Unsatisfactory	Virtually acellular specimen
		Other (obscuring blood, clotting artifact, etc.)
II	Benign	Consistent with a benign follicular nodule (includes adenomatoid nodule,
		colloid nodule, etc.)
		Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical
		context
		Consistent with granulomatous (subacute) thyroiditis
		Other
III	Atypia of Undetermined	
	Significance or Follicular	

The 2017 Bethesda System for Reporting Thyroid Cytopathology

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49 Page: 4 of 7

	× · · · · · ·	
	Lesion of Undetermined	
	Significance	
IV	Follicular Neoplasm or	Specify if Hürthle cell (oncocytic) type
	Suspicious for a Follicular	
	Neoplasm	
V	Suspicious for	Suspicious for papillary carcinoma
	Malignancy	Suspicious for medullary carcinoma
		Suspicious for metastatic carcinoma
		Suspicious for lymphoma
		Other
VI	Malignant	Papillary thyroid carcinoma
		Poorly differentiated carcinoma
		Medullary thyroid carcinoma
		Undifferentiated (anaplastic) carcinoma
		Squamous cell carcinoma
		Carcinoma with mixed features (specify)
		Metastatic carcinoma
		Non-Hodgkin lymphoma
		Other

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT Codes

Code	Description
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
81479	Unlisted molecular pathology procedure
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious (<i>Afirma Genomic Sequencing Classifer, Veracyte, Inc.</i>)
0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy (<i>ThyraMIR</i> [™] , <i>Interpace Diagnostics</i>)
0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") (<i>Thyroseq Genomic Classifier, CBLPath, Inc., University of Pittsburgh</i> <i>Medical Center</i>)

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49

Page:	5	of 7	
-------	---	-------------	--

Code	Description
0204U	Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected (<i>Afirma Xpression Atlas, Veracyte, Inc.</i>)
0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage (<i>ThyGeNEXT</i> ® <i>Thyroid Oncogene Panel, Interpace Diagnostics</i>)
0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) (<i>ThyroSeq</i> ® <i>CRC</i> , <i>CBLPath</i> , <i>Inc</i> , <i>University of Pittsburgh Medical Center</i>) (effective 1/1/2022)

Copyright © 2022 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
No specific codes	

ICD10 Codes

Code	Description
C73	Malignant neoplasm of thyroid gland
D34	Benign neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

REFERENCES

*Alexander EK, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012 Aug 23;267(8):705-15.

Al-Qurayshi Z, et al. Association of malignancy prevalence with test properties and performance of the gene expression classifier in indeterminate thyroid nodules. JAMA Otolaryngol Head Neck Surg 2017 Apr 1:143(4):403-408.

Borowczyk M, et al. Evaluation of 167 gene expression classifier (GEC) and ThyroSeq vs diagnostic accuracy in the preoperative assessment of indeterminate thyroid nodules: bivariate/HROC meta-analysis. Endocr Pathol 2019 Mar;30(1):8-15.

*Cibas ES, et al. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009 Nov;132(5):658-65.

Fazeli FR, et al. ThyroSeq v2 testing: impact on cytologic diagnosis, management, and cost of care in patients with thyroid nodule. Thyroid 2020 Oct;30(10):1528-1534.

Gharib H, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules--2016 update. Endocr Pract. 2016 May;22(5):622-39.

Gortakowski M, et al. Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules. Thyroid 2021 Sep:31(9):1376-1382.

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49 Page: 6 of 7

Harrison G, et al. Evaluation of the Afirma gene expression classifier in repeat indeterminate thyroid nodules. <u>Arch Pathol</u> <u>Lab Med</u> 2017 Jul;141(7):985-989.

Hu TX, et al. The effect modification of ultrasound risk classification on molecular testing in predicting the risk of malignancy in cytologically indeterminate thyroid nodules. <u>Thyroid</u> 2022;32(8):905-916.

Jinih M, et al. BRAFV600E mutation as a predictor of thyroid malignancy in indeterminate nodules: a systematic review and meta-analysis. <u>Eur J Surg Oncol</u> 2017 Jul;43(7):1219-1227.

Jug RC, et al. Molecular testing for indeterminate thyroid nodules: performance of the Afirma Gene Expression Classifier and ThyroSeq panel. <u>Cancer Cytopathol.</u> 2018;126(7):471-480.

Jug R, et al. Negative results on thyroid molecular testing decreases rates of surgery for indeterminate thyroid nodules. <u>Endocr Pathol</u> 2019 Jun;30(2):134-137.

Kay-Rivest E, et al., The first Canadian experience with the Afirma[®] gene expression classifier test. <u>J Otolaryngol Head</u> <u>Neck Surg</u> 2017 Apr 4;46(1):25.

Livhits MJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol 2021:7(1):70-77.

Livhits MJ, et al. Gene expression classifier vs targeted next-generation sequencing in the management of indeterminate thyroid nodules. J Clin Endocrinol Metab 2018;103(6):2261-2264.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Thyroid carcinoma. V.2.2022. [https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf] accessed 09/01/22.

Nicholson KJ, et al. Molecular testing versus diagnostic lobectomy in Bethesda III/IV thyroid nodules: a costeffectiveness analysis. <u>Thyroid</u> 2019 Sep;29(9):1237-1243.

*Nikiforov YE, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next- generation sequencing assay. <u>Cancer</u> 2014 Dec1;120(23):3627-34.

Ospina NS, et al. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ 2020;368:16670.

Partya KL, et al. Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine needle aspiration. <u>Diagn Cytopathol</u> 2019 Sep;47(9):853-862.

Sacks WL, et al. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy. <u>Cancer Cytopathol</u> 2016 Oct;124(10):722-728.

Taye A, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq vs) in the evaluatin of indeterminate thyroid nodules. <u>Surgery</u> 2018 Jan;163(1):97-103.

Zhu CY, et al. Outcomes of indeterminate thyroid nodules managed nonoperatively after molecular testing. <u>J Clin</u> <u>Endocrinol Metab</u> 2021 Mar 8;106(3):e1240-e1247.

*Key Article

KEY WORDS

ThyroSeq, Afirma Gene Sequencing Classifier (GSC), fine needle aspiration of the thyroid, molecular markers of thyroid, ThyGenX Thyroid Oncogene Panel

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) for Molecular Pathology Procedures. Please refer to the following LCD website for Medicare members: <u>https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35000&ver=133&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=All&bc=AAgAAAQBIA AA&</u>

Medical Policy: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID Policy Number: 2.02.49 Page: 7 of 7

There is currently a Local Coverage Article (LCA) for Molecular Pathology Procedures. Please refer to the following LCA website for Medicare members: <u>https://www.cms.gov/medicare-coverage-</u>database/view/article.aspx?articleid=56199&ver=67&

There is a Local Coverage Determination (LCD) for Thyroid Nodule Molecular Testing. Please refer to the following LCD website for Medicare members: <u>https://www.cms.gov/medicare-coverage-</u> <u>database/view/lcd.aspx?lcdid=38968&ver=4&keyword=Thyroid%20Nodule%20Molecular%20Testing&keywordType=st</u> <u>arts&areaId=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc</u>

<u>=1</u>

There is a proposed Local Coverage Article (LCA) for Thyroid Nodule Molecular Testing. Please refer to the following LCA website for Medicare members: <u>https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58655&ver=3</u>